OBIGEN Pharma, Inc

OBIGEN Pharma is the first Taiwan biotech startup specializing in researching, developing, and producing the only 760kDa Type A Botulinum Toxin, OBI-858. Manufactured at OBIGEN’s own PIC/S GMP-compliant API and drug product plants, its proprietary cell line grants OBI-858 wide safety margin, high potency, low diffusion, fast onset, and potential long duration. So far patented in 9 countries, including Japan, Australia, New Zealand, Russia, Saudi Arabia, Indonesia, Malaysia, Singapore, and Taiwan, OBI-858 is now in Phase ll clinical trial in Taiwan. The animal-and-alcohol-free unique excipients also contribute to OBI-858’s Halal Certificate. 
OBIGEN seeks global partnerships to elevate patient care and aesthetics. As a world-class pharma, partnering with OBIGEN will improve your market competitiveness and penetration through a diversified product portfolio, increasing cross-selling opportunities! 
Let’s innovate beauty and health together! 
Email us: contactus@obigenpharma.com